{"id":1371,"date":"2023-01-12T13:57:50","date_gmt":"2023-01-12T16:57:50","guid":{"rendered":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/"},"modified":"2023-01-12T13:57:50","modified_gmt":"2023-01-12T16:57:50","slug":"pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae","status":"publish","type":"post","link":"https:\/\/jamesalbiero.com.br\/en\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/","title":{"rendered":"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing <em>Klebsiella pneumoniae<\/em>."},"content":{"rendered":"<p>In vitro pharmacodynamic study with Monte Carlo simulation evaluating the influence of urinary pH on the action of fosfomycin against E. coli and <em>Klebsiella spp<\/em>, and demonstrated that the reduction in urinary pH favors the pharmacodynamic action of this antimicrobials.<\/p>\n<p><strong>Refer\u00eancia:<\/strong> <strong>Albiero J<\/strong>, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4128-39. doi: 10.1128\/AAC.03099-15<\/p>\n<p><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4914646\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4914646\/<\/a><\/p>\n<p><a href=\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/Pharmacodynamic-Evaluation-of-the-Potential-Clinical-Utility-of-Fosfomycin-and-Meropenem-in-Combination-Therapy-Against-KPC-2-Producing-Klebsiella-pneumoniae..pdf\" target=\"_blank\" rel=\"noopener\">CLICK HERE<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In vitro pharmacodynamic study with Monte Carlo simulation evaluating the influence of urinary pH on the action of fosfomycin against E. coli and Klebsiella spp, and demonstrated that the reduction in urinary pH favors the pharmacodynamic action of this antimicrobials. Refer\u00eancia: Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[39,33],"tags":[],"class_list":["post-1371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-highlights"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae. - James Albiero PhD<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae. - James Albiero PhD\" \/>\n<meta property=\"og:description\" content=\"In vitro pharmacodynamic study with Monte Carlo simulation evaluating the influence of urinary pH on the action of fosfomycin against E. coli and Klebsiella spp, and demonstrated that the reduction in urinary pH favors the pharmacodynamic action of this antimicrobials. Refer\u00eancia: Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\" \/>\n<meta property=\"og:site_name\" content=\"James Albiero PhD\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-12T16:57:50+00:00\" \/>\n<meta name=\"author\" content=\"brnitro\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"brnitro\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\"},\"author\":{\"name\":\"brnitro\",\"@id\":\"https:\/\/jamesalbiero.com.br\/#\/schema\/person\/e2848d0442b9796c78e00a470a25b7f7\"},\"headline\":\"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae.\",\"datePublished\":\"2023-01-12T16:57:50+00:00\",\"dateModified\":\"2023-01-12T16:57:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\"},\"wordCount\":96,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/#organization\"},\"image\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png\",\"articleSection\":[\"Articles\",\"Highlights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\",\"url\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\",\"name\":\"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae. - James Albiero PhD\",\"isPartOf\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png\",\"datePublished\":\"2023-01-12T16:57:50+00:00\",\"dateModified\":\"2023-01-12T16:57:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage\",\"url\":\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png\",\"contentUrl\":\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png\",\"width\":792,\"height\":1021},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/jamesalbiero.com.br\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/jamesalbiero.com.br\/#website\",\"url\":\"https:\/\/jamesalbiero.com.br\/\",\"name\":\"James Albiero PhD\",\"description\":\"Antimicrobial Stewardship\",\"publisher\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/jamesalbiero.com.br\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/jamesalbiero.com.br\/#organization\",\"name\":\"James Albiero PhD\",\"url\":\"https:\/\/jamesalbiero.com.br\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/jamesalbiero.com.br\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2022\/11\/logomenor.png\",\"contentUrl\":\"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2022\/11\/logomenor.png\",\"width\":198,\"height\":61,\"caption\":\"James Albiero PhD\"},\"image\":{\"@id\":\"https:\/\/jamesalbiero.com.br\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/jamesalbiero.com.br\/#\/schema\/person\/e2848d0442b9796c78e00a470a25b7f7\",\"name\":\"brnitro\",\"sameAs\":[\"https:\/\/jamesalbiero.com.br\"],\"url\":\"https:\/\/jamesalbiero.com.br\/en\/author\/brnitro\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae. - James Albiero PhD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/","og_locale":"en_US","og_type":"article","og_title":"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae. - James Albiero PhD","og_description":"In vitro pharmacodynamic study with Monte Carlo simulation evaluating the influence of urinary pH on the action of fosfomycin against E. coli and Klebsiella spp, and demonstrated that the reduction in urinary pH favors the pharmacodynamic action of this antimicrobials. Refer\u00eancia: Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, [&hellip;]","og_url":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/","og_site_name":"James Albiero PhD","article_published_time":"2023-01-12T16:57:50+00:00","author":"brnitro","twitter_card":"summary_large_image","twitter_misc":{"Written by":"brnitro"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#article","isPartOf":{"@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/"},"author":{"name":"brnitro","@id":"https:\/\/jamesalbiero.com.br\/#\/schema\/person\/e2848d0442b9796c78e00a470a25b7f7"},"headline":"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae.","datePublished":"2023-01-12T16:57:50+00:00","dateModified":"2023-01-12T16:57:50+00:00","mainEntityOfPage":{"@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/"},"wordCount":96,"commentCount":0,"publisher":{"@id":"https:\/\/jamesalbiero.com.br\/#organization"},"image":{"@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage"},"thumbnailUrl":"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png","articleSection":["Articles","Highlights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/","url":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/","name":"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae. - James Albiero PhD","isPartOf":{"@id":"https:\/\/jamesalbiero.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage"},"image":{"@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage"},"thumbnailUrl":"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png","datePublished":"2023-01-12T16:57:50+00:00","dateModified":"2023-01-12T16:57:50+00:00","breadcrumb":{"@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#primaryimage","url":"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png","contentUrl":"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2023\/01\/pharmacodynamic-evalueation-potenctial-fosmycin-james-albiero.png","width":792,"height":1021},{"@type":"BreadcrumbList","@id":"https:\/\/jamesalbiero.com.br\/pharmacodynamic-evaluation-of-the-potential-clinical-utility-of-fosfomycin-and-meropenem-in-combination-therapy-against-kpc-2-producing-klebsiella-pneumoniae\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/jamesalbiero.com.br\/en\/"},{"@type":"ListItem","position":2,"name":"Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy Against KPC-2-Producing Klebsiella pneumoniae."}]},{"@type":"WebSite","@id":"https:\/\/jamesalbiero.com.br\/#website","url":"https:\/\/jamesalbiero.com.br\/","name":"James Albiero PhD","description":"Antimicrobial Stewardship","publisher":{"@id":"https:\/\/jamesalbiero.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/jamesalbiero.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/jamesalbiero.com.br\/#organization","name":"James Albiero PhD","url":"https:\/\/jamesalbiero.com.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/jamesalbiero.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2022\/11\/logomenor.png","contentUrl":"https:\/\/jamesalbiero.com.br\/wp-content\/uploads\/2022\/11\/logomenor.png","width":198,"height":61,"caption":"James Albiero PhD"},"image":{"@id":"https:\/\/jamesalbiero.com.br\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/jamesalbiero.com.br\/#\/schema\/person\/e2848d0442b9796c78e00a470a25b7f7","name":"brnitro","sameAs":["https:\/\/jamesalbiero.com.br"],"url":"https:\/\/jamesalbiero.com.br\/en\/author\/brnitro\/"}]}},"_links":{"self":[{"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/posts\/1371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/comments?post=1371"}],"version-history":[{"count":0,"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/posts\/1371\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/media\/1144"}],"wp:attachment":[{"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/media?parent=1371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/categories?post=1371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jamesalbiero.com.br\/en\/wp-json\/wp\/v2\/tags?post=1371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}